Drugs / Trifluridine/Tipiracil
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03799731 | Jul 2018 → Jan 2021 | colorectal cancer | GamaMabs Pharma | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trifluridine/Tipiracil | “Drug: Trifluridine/Tipiracil” NCT03799731 ↗ |
| Route | Oral | “trifluridine/tipiracil will be orally administered” NCT03799731 ↗ |